Biotech companies are at the centre of future success, with one investment group setting its sights on the industry.

These are the companies working to help us live longer, healthier lives by creating cutting edge treatments for devastating diseases.

Merchant Funds’ new Biotech fund focuses on emerging Australian biotech, medical and health sciences companies, giving retail investors the chance to own a piece of this exciting growth industry.

CEO Andrew Chapman joins Brooke Corte to explain the exciting opportunities.

Press PLAY below to hear more from Merchant Group